Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Synovial 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Lymphoma 1Liposarcoma, Myxoid 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Graft vs Host Disease 1Chondrosarcoma 1Adenoma, Liver Cell 1

Interventions

Filgrastim 4Proton Therapy 3Docetaxel 3regorafenib 2Sunitinib 2Ifosfamide 2Gemcitabine 2Carboplatin 2temsirolimus 1pegfilgrastim 1liposomal doxorubicin 1lentiviral minigene vaccine of COVID-19 coronavirus 1ivosidenib 1itacitinib 1etoposide phosphate 1capivasertib 1baricitinib 1apatinib 1angiotensin I (1-7) 1abemaciclib 1Zoledronic Acid 1Weight-Bearing 1Trabectedin 1Topotecan 1Thiotepa 1Thalidomide 1Taxes 1TQ-B3525 1Surveys and Questionnaires 1Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Chondrosarcoma × baricitinib × Clear all
NCT03670069 2024-05-08

Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

Fred Hutchinson Cancer Center

Phase 1 Terminated
27 enrolled
Sarcoma

Chondrosarcoma, Leiomyosarcoma, Sarcoma, Sarcoma, Synovial, Liposarcoma, Myxoid, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡